Successful Application of Whole Genome Sequencing in a Medical Genetics Clinic

Abstract

A pilot program was initiated using whole genome sequencing (WGS) to diagnose suspected genetic disorders in the Genetics Clinic at Children's Hospital of Wisconsin. Twenty-two patients underwent WGS between 2010 and 2013. Initially, we obtained a 14% (3/22) diagnosis rate over 2 years; with subsequent reanalysis, this increased to 36% (8/22). Disease causing variants were identified in SKIV2L, CECR1, DGKE, PYCR2, RYR1, PDGFRB, EFTUD2, and BCS1L. In 75% (6/8) of diagnosed cases, the diagnosis affected treatment and/or medical surveillance. Additionally, one case demonstrated a homozygous A18V variant in VLDLR that appears to be associated with a previously undescribed phenotype.

Keywords

genome - sequencing - diagnosis - clinic

• References

• 1 Rabbani B, Tekin M, Mahdieh N. The promise of whole-exome sequencing in medical genetics. J Hum Genet 2014; 59 (1) 5-15
• 2 Worthey EA, Mayer AN, Syverson GD , et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med 2011; 13 (3) 255-262
• 3 Gahl WA, Boerkoel CF, Boehm M. The NIH Undiagnosed Diseases Program: bonding scientists and clinicians. Dis Model Mech 2012; 5 (1) 3-5
• 4 Gahl WA, Mulvihill JJ, Toro C , et al; UDN. The NIH Undiagnosed Diseases Program and Network: applications to modern medicine. Mol Genet Metab 2016; 117 (4) 393-400
• 5 Yang Y, Muzny DM, Xia F , et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA 2014; 312 (18) 1870-1879
• 6 Etterer K, Juusola J, Cho MT , et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med 2016; 18 (7) 696-704
• 7 Sawyer SL, Hartley T, Dyment DA , et al; FORGE Canada Consortium; Care4Rare Canada Consortium. Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care. Clin Genet 2016; 89 (3) 275-284
• 8 Nolan D, Carlson M. Whole exome sequencing in pediatric neurology patients: clinical implications and estimated cost analysis. J Child Neurol 2016; 31 (7) 887-894
• 9 Gilissen C, Hehir-Kwa JY, Thung DT , et al. Genome sequencing identifies major causes of severe intellectual disability. Nature 2014; 511 (7509): 344-347
• 10 Stark Z, Tan TY, Chong B , et al; Melbourne Genomics Health Alliance. A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders. Genet Med 2016; 2016: 1-7
• 11 Stavropoulos DJ, Merico D, Jobling R , et al. Whole-genome sequencing expands diagnostic utility and improves clinical management in paediatric medicine. npj Genomic Med 2016; 1: 15012 . Doi: 10.1038/npjgenmed.2015.12
• 12 Posey JE, Rosenfeld JA, James RA , et al. Molecular diagnostic experience of whole-exome sequencing in adult patients. Genet Med 2016; 18 (7) 678-685
• 13 Parsons DW, Roy A, Yang Y , et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol 2016; 1200 (5) 1-9
• 14 Miller NA, Farrow EG, Gibson M , et al. A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases. Genome Med 2015; 7 (1) 100 . Doi: 10.1186/s13073-015-0221-8
• 15 Bowdin S, Gilbert A, Bedoukian E , et al. Recommendations for the integration of genomics into clinical practice. Genet Med 2016; 18 (11) 1075-1084
• 16 Delaney SK, Hultner ML, Jacob HJ , et al. Toward clinical genomics in everyday medicine: perspectives and recommendations. Expert Rev Mol Diagn 2016; 16 (5) 521-532
• 17 Fogel BL, Satya-Murti S, Cohen BH. Clinical exome sequencing in neurologic disease. Neurol Clin Pract 2016; 6 (2) 164-176
• 18 Dewey FE, Grove ME, Pan C , et al. Clinical interpretation and implications of whole-genome sequencing. JAMA 2014; 311 (10) 1035-1045
• 19 Lapin V, Mighion LC, da Silva CP, Cuperus Y, Bean LJH, Hegde MR. Regulating whole exome sequencing as a diagnostic test. Hum Genet 2016; 135 (6) 655-673
• 20 Weitzel KW, Alexander M, Bernhardt BA , et al; IGNITE Network. The IGNITE network: a model for genomic medicine implementation and research. BMC Med Genomics 2016; 9 (1) 1 . Doi: 10.1186/s12920-015-0162-5
• 21 Bick D, Dimmock D. Whole exome and whole genome sequencing. Curr Opin Pediatr 2011; 23 (6) 594-600
• 22 Strong KA, Derse AR, Dimmock DP , et al. In the absence of evidentiary harm, existing societal norms regarding parental authority should prevail. Am J Bioeth 2014; 14 (3) 24-26
• 23 Worthey EA. Analysis and annotation of whole-genome or whole-exome sequencing-derived variants for clinical diagnosis. Curr Protoc Hum Genet 2013; 79 (Suppl. 79) 24 . Doi: 10.1002/0471142905.hg0924s79
• 24 Sherry ST, Ward MH, Kholodov M , et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29 (1) 308-311
• 25 Auton A, Brooks LD, Durbin RM , et al. A global reference for human genetic variation. 1000 Genomes Project Consortium. Nature 2015; 526 (7571): 68-74
• 26 Exome Variant Server. http://evs.gs.washington.edu/EVS/ . Accessed January 1, 2016
• 27 Adzhubei IA, Schmidt S, Peshkin L , et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7 (4) 248-249
• 28 Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011; 39 (17) e118 . Doi: 10.1093/nar/gkr407
• 29 Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4 (7) 1073-1081
• 30 Hubisz MJ, Pollard KS, Siepel A. PHAST and RPHAST: phylogenetic analysis with space/time models. Brief Bioinform 2011; 12 (1) 41-51
• 31 Stenson P, Mort M, Ball E, Shaw K, Phillips A, Cooper D. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Human Genet 2014; 133 (1) 1-9
• 32 OMIM. Nathans Institute of Genetic Medicine. Johns Hopkins University. http://www.omim.org/ . Accessed January 1, 2016
• 33 Richards CS, Bale S, Bellissimo DB , et al; Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med 2008; 10 (4) 294-300
• 34 Jacob HJ, Abrams K, Bick DP , et al. Genomics in clinical practice: lessons from the front lines. Sci Transl Med 2013; 5 (194) 194cm5 . Doi: 10.1126/scitranslmed.3006468
• 35 Zhou Q, Yang D, Ombrello AK , et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014; 370 (10) 911-920
• 36 Kruer MC, Jepperson TN, Weimer JM , et al. Mutations in VLDLR associated with ataxia with secondary vitamin E deficiency. Mov Disord 2013; 28 (13) 1904-1905
• 37 Eculizumab . Formulary Journal http://formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/eculizumab . Published 2007. Accessed January 1, 2016
• 38 Gene Map Statistics OMIM. http://www.omim.org/statistics/geneMap . Published 2016 . Accessed July 15, 2016
• 39 Gillis E, Kempers M, Salemink S , et al. An FBN1 deep intronic mutation in a familial case of Marfan syndrome: an explanation for genetically unsolved cases?. Hum Mutat 2014; 35 (5) 571-574
• 40 Qian Y, Johnson JA, Connor JA , et al. The 253-kb inversion and deep intronic mutations in UNC13D are present in North American patients with familial hemophagocytic lymphohistiocytosis 3. Pediatr Blood Cancer 2014; 61 (6) 1034-1040
• 41 Lazaridis KN, McAllister TM, Babovic-Vuksanovic D , et al. Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet 2014; 166C (1) 15-23
• 42 Dorschner MO, Amendola LM, Turner EH , et al; National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project. Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet 2013; 93 (4) 631-640
• 43 Sikkema-Raddatz B, Johansson LF, de Boer EN , et al. Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum Mutat 2013; 34 (7) 1035-1042
• 44 Strom SP, Lee H, Das K , et al. Assessing the necessity of confirmatory testing for exome-sequencing results in a clinical molecular diagnostic laboratory. Genet Med 2014; 16 (7) 510-515
• 45 Baudhuin LM, Lagerstedt SA, Klee EW, Fadra N, Oglesbee D, Ferber MJ. Confirming variants in next-generation sequencing panel testing by sanger sequencing. J Mol Diagn 2015; 17 (4) 456-461
• 46 Green RC, Berg JS, Grody WW , et al; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15 (7) 565-574
• 47 Burke W, Antommaria AH, Bennett R , et al. Recommendations for returning genomic incidental findings? We need to talk!. Genet Med 2013; 15 (11) 854-859
• 48 Borry P, Evers-Kiebooms G, Cornel MC, Clarke A, Dierickx K ; Public and Professional Policy Committee (PPPC) of the European Society of Human Genetics (ESHG). Genetic testing in asymptomatic minors: background considerations towards ESHG Recommendations. Eur J Hum Genet 2009; 17 (6) 711-719
• 49 Shahmirzadi L, Chao EC, Palmaer E, Parra MC, Tang S, Gonzalez KDF. Patient decisions for disclosure of secondary findings among the first 200 individuals undergoing clinical diagnostic exome sequencing. Genet Med 2014; 16 (5) 395-399
• 50 Yushak ML, Han G, Bouberhan S , et al. Patient preferences regarding incidental genomic findings discovered during tumor profiling. Cancer 2016; 122 (10) 1588-1597
• 51 Nelson MR, Wegmann D, Ehm MG , et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science 2012; 337 (6090): 100-104
• 52 Keinan A, Clark AG. Recent explosive human population growth has resulted in an excess of rare genetic variants. Science 2012; 336 (6082): 740-743
• 53 Richards S, Aziz N, Bale S , et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (5) 405-424
• 54 Philippakis AA, Azzariti DR, Beltran S , et al. The Matchmaker exchange: a platform for rare disease gene discovery. Hum Mutat 2015; 36 (10) 915-921
• 55 Landrum MJ, Lee JM, Benson M , et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res 2016; 44 (D1) D862-D868
• 56 van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. Ten years of next-generation sequencing technology. Trends Genet 2014; 30 (9) 418-426
• 57 Clinical Services Lab - FAQS. https://clinicallab.org/faqs/ . Accessed August 4, 2016
• 58 Illumina TruGenome Clinical Sequencing Services. http://www.illumina.com/clinical/illumina_clinical_laboratory/trugenome-clinical-sequencing-services.html . Accessed August 4, 2016
• 59 NHGRI. Genomic Medicine Centers Meeting IV. physician education in genomics. https://www.genome.gov/27552294/ . Accessed January 1, 2016
• 60 Gustafson SL, Pfeiffer G, Eng C. A large health system's approach to utilization of the genetic counselor CPT® 96040 code. Genet Med 2011; 13 (12) 1011-1014
• 61 Dougherty MJ, Wicklund C, Johansen Taber KA. Challenges and opportunities for genomics education: insights from an Institute of Medicine Roundtable Activity. J Contin Educ Health Prof 2016; 36 (1) 82-85
• 62 Köhler S, Doelken SC, Mungall CJ , et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Res 2014; 42 (database issue): D966-D974
• 63 Wang L, Zhang C, Watkins J, Jin Y, McNutt M, Yin Y. SoftPanel: a website for grouping diseases and related disorders for generation of customized panels. BMC Bioinformatics 2016; 17 (1) 153 . Doi: 10.1186/s12859-016-0998-5
• 64 Smedley D, Robinson PN. Phenotype-driven strategies for exome prioritization of human Mendelian disease genes. Genome Med 2015; 7 (1) 81 . Doi: 10.1186/s13073-015-0199-2